Carnegie Mellon Researchers Demonstrate That LLMs Can Autonomously Plan and Execute Real-World Cyberattacks
24.7.2025 15:05:00 CEST | Business Wire | Press Release
In a major advance in the fields of cybersecurity and artificial intelligence, researchers from Carnegie Mellon University, in collaboration with Anthropic, have demonstrated that large language models (LLMs) can autonomously plan and execute sophisticated cyberattacks on enterprise-grade network environments without human intervention.
The study, led by Ph.D. candidate Brian Singer from Carnegie Mellon's Department of Electrical and Computer Engineering, reveals that LLMs, when structured with high-level planning capabilities and supported by specialized agent frameworks, can simulate network intrusions that closely mirror real-world breaches. The study’s most striking finding: an LLM was able to successfully replicate the infamous 2017 Equifax data breach in a controlled research environment—autonomously exploiting vulnerabilities, installing malware, and exfiltrating data.
“Our research shows that with the right abstractions and guidance, LLMs can go far beyond basic tasks,” said Singer. “They can coordinate and execute attack strategies that reflect real-world complexity.”
The team developed a hierarchical architecture where the LLM acts as a strategist, planning the attack and issuing high-level instructions, while a mix of LLM and non-LLM agents carry out low-level tasks like scanning networks or deploying exploits. This approach proved far more effective than earlier methods, which relied solely on LLMs executing shell commands.
This work builds on Singer’s prior research into making autonomous attacker and defender tools more accessible and programmable for human developers. Ironically, the same abstractions that simplified development for humans made it easier for LLMs to autonomously perform similar tasks.
While the findings are groundbreaking, Singer emphasized that the research remains a prototype.
“This isn’t something that’s going to take down the internet tomorrow,” he said. “The scenarios are constrained and controlled—but it’s a powerful step forward.”
The implications are twofold: the research highlights serious long-term safety concerns about the potential misuse of increasingly capable LLMs, but it also opens up transformative possibilities for defensive cybersecurity.
“Today, only large organizations can afford red team exercises to proactively test their defenses,” Singer explained. “This research points toward a future where AI systems continuously test networks for vulnerabilities, making these protections accessible to small organizations too.”
The project was conducted in collaboration with Anthropic, which provided model credits and technical consultation. The team included CMU students and faculty affiliated with CyLab, the university’s security and privacy institute. An early version of the research was presented at an OpenAI-hosted security workshop in May.
The resulting paper, “On the Feasibility of Using LLMs to Autonomously Execute Multi-host Network Attacks,” has been cited in multiple industry reports and is already informing safety documentation for cutting-edge AI systems. Lujo Bauer and Vyas Sekar, co-directors of CMU’s Future Enterprise Security Initiative, served as faculty advisors for the project.
Looking ahead, the team is now studying how similar architectures might enable autonomous AI defenses, exploring scenarios where LLM-based agents detect and respond to attacks in real time.
“We're entering an era of AI versus AI in cybersecurity,” Singer said. “And we need to understand both sides to stay ahead.”
About the College of Engineering: The College of Engineering at Carnegie Mellon University is a top-ranked engineering college that is known for our intentional focus on cross-disciplinary collaboration in research. The College is well-known for working on problems of both scientific and practical importance. Our “maker” culture is ingrained in all that we do, leading to novel approaches and transformative results. Our acclaimed faculty have a focus on innovation management and engineering to yield transformative results that will drive the intellectual and economic vitality of our community, nation, and world.
About CyLab:CyLab is the university-wide security and privacy institute at Carnegie Mellon University. We coordinate security and privacy research and education across all university departments. Our mission is to catalyze, support, promote, and strengthen collaborative security and privacy research and education across departments, disciplines, and geographic boundaries to achieve significant impact on research, education, public policy, and practice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724351815/en/
Contacts
Media Contact:
Michael Cunningham
Carnegie Mellon University
mcunningham@cmu.edu
412-443-2051
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom